Login to Your Account



Search

Search results

Pharma: Clinic Roundup

• Merck and Co. Inc. , of Whitehouse Station, N.J., said that in a Phase III study, its vaccine for human papilloma virus (HPV), V503, prevented 97 percent of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52 and 58. ...

BioWorld Today - Staff - 2013-11-05 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Sunovion Pharmaceuticals Inc. , of Marlborough, Mass., published results from two pivotal trials supporting FDA approval of Latuda (lurasidone HCL) for major depressive episodes associated with bipolar I disorder in The American Journal of ...

BioWorld Today - Staff - 2013-11-04 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Merck & Co. Inc. , of Whitehouse Station, N.J., presented interim data from a Phase Ib trial of MK-3475, for non-small-cell lung cancer at the World Conference on Lung Cancer in Sydney. (BioWorld-Today-2013-10-30) ...

BioWorld Today - Staff - 2013-10-30 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Boehringer Ingelheim GmbH , of Ingelheim, Germany, presented data at the American College of Chest Physicians meeting in Chicago from Phase II and Phase III studies testing tiotropium in asthma. (BioWorld-Today-2013-10-29) ...

BioWorld Today - Staff - 2013-10-29 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Sihuan Pharmaceutical Holdings Group Ltd. , of Hong Kong, said the China Food and Drug Administration accepted its application for clinical trial approval of pirotinib. In preclinical studies, the second-generation inhibitor, aimed at the treatment ...

BioWorld Today - Staff - 2013-10-11 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Pfizer Inc ., of New York, reported top-line results from two Phase III trials of tofacitinib, an oral Janus kinase (JAK) inhibitor being investigated to treat adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OP ...

BioWorld Today - Staff - 2013-10-10 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, disclosed results of a Phase I/II study of its intramuscular bivalent (GI/GII) norovirus vaccine candidate in healthy adult volunteers who were challenged with the most commonly occurring noroviru ...

BioWorld Today - Staff - 2013-10-07 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Abbvie Inc. , of Chicago, shared results of a posthoc analysis of a Phase II study of Humira (adalimumab) for patients with hidradenitis suppurativa. The analysis showed that Humira produced a significant response rate in patients with moderate ...

BioWorld Today - Staff - 2013-10-04 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Eli Lilly and Co. , of Indianapolis, disclosed positive patient-reported health outcomes from a Phase III trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 receptor agonist being studied as a once-weekly treatment for ...

BioWorld Today - Staff - 2013-09-27 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Janssen Research and Development LLC , of Raritan, N.J., a unit of Johnson & Johnson, said results from a 52-week analysis of a Phase III trial of Invokana (canagliflozin) showed substantial improvements in glycemic control for patients with Ty ...

BioWorld Today - Staff - 2013-09-25 00:00 - 0 comments - 0 attachments